A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor.

Trial Profile

A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications Trophoblastic tumour
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 23 May 2007 Status changed from in progress to completed.
    • 12 May 2007 Status changed from recruiting to in progress.
    • 24 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top